Apellis Pharmaceuticals Inc (NASDAQ:APLS) — Market Cap & Net Worth
Market Cap & Net Worth: Apellis Pharmaceuticals Inc (APLS)
Apellis Pharmaceuticals Inc (NASDAQ:APLS) has a market capitalization of $412.48 Million ($412.48 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13326 globally and #3234 in its home market, demonstrating a -2.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apellis Pharmaceuticals Inc's stock price $3.22 by its total outstanding shares 128021277 (128.02 Million). Also see Apellis Pharmaceuticals Inc total assets for a full breakdown of the balance sheet.
Apellis Pharmaceuticals Inc Market Cap History: 2017 to 2026
Apellis Pharmaceuticals Inc's market capitalization history from 2017 to 2026. Data shows change from $2.78 Billion to $412.48 Million (-15.36% CAGR). Also see Apellis Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Apellis Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #363 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1299 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.02% | #199 of 263 |
Weight: Apellis Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Apellis Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apellis Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Apellis Pharmaceuticals Inc (APLS) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.20x
Apellis Pharmaceuticals Inc's market cap is 3.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
143.64x
Apellis Pharmaceuticals Inc's market cap is 143.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $7.32 Billion | $250.65 Million | -$344.87 Million | 29.22x | N/A |
| 2021 | $6.05 Billion | $66.56 Million | -$746.35 Million | 90.93x | N/A |
| 2022 | $6.62 Billion | $75.42 Million | -$652.17 Million | 87.77x | N/A |
| 2023 | $7.66 Billion | $396.59 Million | -$528.63 Million | 19.32x | N/A |
| 2024 | $4.09 Billion | $781.37 Million | -$197.88 Million | 5.23x | N/A |
| 2025 | $3.22 Billion | $1.00 Billion | $22.39 Million | 3.20x | 143.64x |
Competitor Companies of APLS by Market Capitalization
Companies near Apellis Pharmaceuticals Inc in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Apellis Pharmaceuticals Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Apellis Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Apellis Pharmaceuticals Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Apellis Pharmaceuticals Inc's market cap moved from $2.78 Billion to $ 412.48 Million, with a yearly change of -15.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $412.48 Million | -87.17% |
| 2025 | $3.22 Billion | -21.28% |
| 2024 | $4.09 Billion | -46.69% |
| 2023 | $7.66 Billion | +15.76% |
| 2022 | $6.62 Billion | +9.37% |
| 2021 | $6.05 Billion | -17.34% |
| 2020 | $7.32 Billion | +86.81% |
| 2019 | $3.92 Billion | +132.15% |
| 2018 | $1.69 Billion | -39.22% |
| 2017 | $2.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Apellis Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $412.48 Million USD |
| MoneyControl | $412.48 Million USD |
| MarketWatch | $412.48 Million USD |
| marketcap.company | $412.48 Million USD |
| Reuters | $412.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more